Innovative Utilization of Orange Peel Waste through Modified Citrus Pectin (MCP) as a Preventive Agent Against Atherosclerosis Progression via Galectin-3 (Gal-3) Inhibition: A Comprehensive Literature Review on In Vitro and In Vivo Study Designs
DOI:
https://doi.org/10.58794/jim.v2i2.889Keywords:
Atherosclerotic, Gal-3, MCP, Therapy, RegulationAbstract
Atherosclerosis is an arterial disease often associated with lipids and other metabolic alterations. Various factors are involved in developing atherosclerosis, including Galectin-3 (Gal-3). Pre-clinical studies have shown that Modified Citrus Pectin (MCP), a modified polysaccharide from citrus peels, has the potential of inhibiting Gal-3 and countering the development of atherosclerosis. Thus, this review aims to analyze the role of MCP on inhibiting and regulating Galectin-3 (Gal-3) as an alternative therapeutic target. We examined valid pre-clinical experimental study designs taken from the databases Science Direct, Taylor & Francis, PubMed, and Google Scholar, with publication dates ranging from 2014 to 2024. 15 research articles meet the established inclusion criteria. Our review found that Gal-3 levels rose during atherosclerosis development, triggering proteins that disturbs cardiovascular physiology. Additionally, Gal-3 targeted inhibition using MCP has shown to have therapeutic effects that alleviates hypertrophy and plaque’s size. In essence, MCP emerges as a promising alternative therapy targeting Gal-3 in atherosclerosis progression.
References
] Barquera S, Pedroza-Tobías A, Medina C, Hernández-Barrera L, Bibbins-Domingo K, Lozano R, et al. Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease. Archives of Medical Research [Internet]. 2015 Jul 1 [cited 2024 Jun 3];46(5):328–38. Available from: https://www.sciencedirect.com/science/article/pii/S0188440915001423
] Khan MA, Hashim MJ, Mustafa H, Baniyas MY, Al Suwaidi SKBM, AlKatheeri R, et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. Cureus. 2020 Jul 23;12(7):e9349.
] Riskesdes. Epidemiologi Penyakit Jantung Koroner di Indonesia Tahun 2013-2018. Kementerian Kesehatan Republik Indonesia. 2018th ed. :220.
] Rafieian-Kopaei M, Setorki M, Doudi M, Baradaran A, Nasri H. Atherosclerosis: Process, Indicators, Risk Factors and New Hopes. Int J Prev Med [Internet]. 2014 Aug [cited 2024 May 24];5(8):927–46. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258672/
] Douglas G, Channon KM. The pathogenesis of atherosclerosis. Medicine [Internet]. 2014 Sep 1 [cited 2024 Jun 3];42(9):480–4. Available from: https://www.sciencedirect.com/science/article/pii/S1357303914001893
] Blanda V, Bracale UM, Di Taranto MD, Fortunato G. Galectin-3 in Cardiovascular Diseases. International Journal of Molecular Sciences [Internet]. 2020 Jan [cited 2024 May 24];21(23):9232. Available from: https://www.mdpi.com/1422-0067/21/23/9232
] Xu GR, Zhang C, Yang HX, Sun JH, Zhang Y, Yao T ting, et al. Modified citrus pectin ameliorates myocardial fibrosis and inflammation via suppressing galectin-3 and TLR4/MyD88/NF-κB signaling pathway. Biomedicine & Pharmacotherapy [Internet]. 2020 Jun 1 [cited 2024 May 23];126:110071. Available from: https://www.sciencedirect.com/science/article/pii/S0753332220302626
] Matilla L, Martín-Núñez E, Garaikoetxea M, Navarro A, Tamayo I, Fernández-Celis A, et al. Sex-specific role of galectin-3 in aortic stenosis. Biology of Sex Differences [Internet]. 2023 [cited 2024 May 23];14. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598900/
] Lu Y, Zhang M, Zhao P, Jia M, Liu B, Jia Q, et al. Modified citrus pectin inhibits galectin-3 function to reduce atherosclerotic lesions in apoE-deficient mice. Mol Med Rep [Internet]. 2017 Jul [cited 2024 May 23];16(1):647–53. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482107/
] Zhang T, Lan Y, Zheng Y, Liu F, Zhao D, Mayo KH, et al. Identification of the bioactive components from pH-modified citrus pectin and their inhibitory effects on galectin-3 function. Food Hydrocolloids [Internet]. 2016 Jul [cited 2024 Jun 4];58:113–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0268005X16300509
] Lim SH, Kim MY, Lee J. Apple pectin, a dietary fiber, ameliorates myocardial injury by inhibiting apoptosis in a rat model of ischemia/reperfusion. Nutrition Research and Practice [Internet]. 2014 Aug 1 [cited 2024 May 23];8(4):391–7. Available from: https://doi.org/10.4162/nrp.2014.8.4.391
] Vergaro G, Prud’homme M, Fazal L, Merval R, Passino C, Emdin M, et al. Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice. Hypertension [Internet]. 2016 Mar [cited 2024 May 23]; Available from: https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.115.06161
] Sádaba JR, Martínez‐Martínez E, Arrieta V, Álvarez V, Fernández‐Celis A, Ibarrola J, et al. Role for Galectin‐3 in Calcific Aortic Valve Stenosis. J Am Heart Assoc [Internet]. 2016 Nov 4 [cited 2024 May 23];5(11):e004360. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5210369/
] Mo D, Tian W, Zhang HN, Feng YD, Sun Y, Quan W, et al. Cardioprotective effects of galectin-3 inhibition against ischemia/reperfusion injury. European Journal of Pharmacology [Internet]. 2019 Nov 15 [cited 2024 May 23];863:172701. Available from: https://www.sciencedirect.com/science/article/pii/S0014299919306533
] Li Y, Zhou WW, Sun JH, Yang HX, Xu GR, Zhang Y, et al. Modified citrus pectin prevents isoproterenol-induced cardiac hypertrophy associated with p38 signalling and TLR4/JAK/STAT3 pathway. Biomedicine & Pharmacotherapy [Internet]. 2021 Nov 1 [cited 2024 May 23];143:112178. Available from: https://www.sciencedirect.com/science/article/pii/S0753332221009628
] Martínez-Martínez E, Calvier L, Fernández-Celis A, Rousseau E, Jurado-López R, Rossoni LV, et al. Galectin-3 Blockade Inhibits Cardiac Inflammation and Fibrosis in Experimental Hyperaldosteronism and Hypertension. Hypertension [Internet]. 2015 Oct [cited 2024 Jun 1];66(4):767–75. Available from: https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.115.05876
] Wang G, Li R, Feng C, Li K, Liu S, Fu Q. Galectin-3 is involved in inflammation and fibrosis in arteriogenic erectile dysfunction via the TLR4/MyD88/NF-κB pathway. Cell Death Discov [Internet]. 2024 Feb 20 [cited 2024 May 23];10(1):1–11. Available from: https://www.nature.com/articles/s41420-024-01859-x
] Pozder geb. Gehlken C, Rogier van der Velde A, Meijers WC, Silljé HHW, Muntendam P, Dokter MM, et al. Pectins from various sources inhibit galectin-3-related cardiac fibrosis. Current Research in Translational Medicine [Internet]. 2022 Jan 1 [cited 2024 May 23];70(1):103321. Available from: https://www.sciencedirect.com/science/article/pii/S2452318621000477
] Wan Q, Zhang L, Han Y, Li Z, Li B. Protection of CAPE-pNO2 Against Chronic Myocardial Ischemia by the TGF-Β1/Galectin-3 Pathway in Vivo and in Vitro [Internet]. 2021 [cited 2024 Jun 1]. Available from: https://www.researchsquare.com/article/rs-912404/v1
] Li S, Li S, Hao X, Zhang Y, Deng W. Perindopril and a Galectin-3 Inhibitor Improve Ischemic Heart Failure in Rabbits by Reducing Gal-3 Expression and Myocardial Fibrosis. Front Physiol [Internet]. 2019 Mar 22 [cited 2024 May 23];10. Available from: https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2019.00267/full
] Martínez-Martínez E, Brugnolaro C, Ibarrola J, Ravassa S, Buonafine M, López B, et al. CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation. Hypertension [Internet]. 2019 Mar [cited 2024 May 23];73(3):602–11. Available from: https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.118.11874
] Ibarrola J, Martínez-Martínez E, Sádaba JR, Arrieta V, García-Peña A, Álvarez V, et al. Beneficial Effects of Galectin-3 Blockade in Vascular and Aortic Valve Alterations in an Experimental Pressure Overload Model. International Journal of Molecular Sciences [Internet]. 2017 Aug [cited 2024 May 23];18(8):1664. Available from: https://www.mdpi.com/1422-0067/18/8/1664
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 JIM - Journal International Multidisciplinary
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
JIM - Multidisciplinary International Journal provides open access to anyone, ensuring that the information and findings in the article are useful to everyone. This journal article's entire contents can be accessed and downloaded for free. In accordance with the Creative Commons Attribution-ShareAlike 4.0 International License.
JIM-Multidisciplinary International Journa is licensed under a Creative Commons Attribution-ShareAlike 4.0
